ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Clinical trials for ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New breast cancer pill combo shows promise in Late-Stage trial
Disease control OngoingThis Phase 3 trial tests a new experimental drug, vepdegestrant, combined with palbociclib against the standard treatment (letrozole plus palbociclib) for people with advanced ER+/HER2- breast cancer that has not been treated before. The study aims to see if the new combination w…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests whether adding a targeted drug (PD 0332991) to standard hormone therapy (anastrozole) before surgery can better stop breast cancer cell growth in women with early-stage ER+ HER2- breast cancer. About 84 women with stage 2 or 3 disease will receive the combination…
Matched conditions: ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC